Navitoclax plus ruxolitinib in JAK inhibitor-naive patients with myelofibrosis: Preliminary safety and efficacy in a multicenter, open-label phase 2 study

Navitoclax (NAV) is an oral, small-molecule inhibitor of BCL-X_L and BCL-2 that has been shown to have a synergistic effect when used in combination with JAK inhibitors to enhance apoptosis. Results from interim analysis of an ongoing phase 2 clinical trial evaluating the efficacy and safety of NAV with/without ruxolitinib in patients with myelofibrosis show that this combination is well tolerated. Additionally, the investigators are seeing early and robust reductions in spleen volume, anemia and bone marrow fibrosis.